Explore how Insilico collaborates with Servier to advance AI-driven drug discovery in oncology for unmet medical needs.
News-Medical.Net on MSN
OutSee completes seed funding round and establishes partnership with o2h discovery for lead drug target candidate
OutSee, a genomics and drug discovery company pioneering a unique AI-based predictive genomics approach to target discovery, today announced the closure of its £2.5 M seed funding round.
Insilico Medicine (“Insilico”), a world-leading artificial intelligence (AI)-driven drug discovery company, today announced a ...
Zhongyao Ma, PhD, holds a bachelor’s degree in biology from Shanghai Jiao Tong University and a PhD in genetics and developmental biology from the University of Georgia, U.S. His research focused on ...
LOS ANGELES, CA / ACCESS Newswire / August 6, 2025 / Today MAX BioPharma, Inc. (www.maxbiopharma.com) and Revilico, Inc. (www.revilico.bio) announced their collaboration in studying the mechanisms of ...
Headlamp Health has launched Lumos AI®, a new decision-support platform designed to bring greater precision to neuroscience ...
The post MAX BioPharma and Revilico Announce Collaboration on Target Identification and Mechanistic Studies for Oxysterol Drug Candidates appeared first on Local News Hub. Information contained on ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback